Intervention News

ATLANTA — Use of a coronary sinus reducer improved chest pain symptoms and quality of life for patients with significant coronary artery disease, despite not improving myocardial blood flow, a speaker reported.

ATLANTA — Preventive PCI plus optimal medical therapy was superior to optimal medical therapy alone for patients with nonflow-limiting vulnerable coronary plaques, according to the results of the PREVENT trial.

ATLANTA — In the DanGer-Shock trial, routine use of a microaxial flow pump, on top of standard care, led to a lower risk for death compared with standard care only for treatment of patients with STEMI and cardiogenic shock.

ATLANTA — In a real-world population of patients with severe aortic stenosis at low or intermediate surgical risk, transcatheter aortic valve replacement was noninferior to surgery for death and stroke at 1 year, researchers reported.

ATLANTA — Adults with uncontrolled and treatment-resistant hypertension saw a modest reduction in 24-hour ambulatory BP with alcohol-mediated renal nerve denervation, although other mixed findings complicate the picture, researchers reported.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.

ATLANTA — In patients with severe aortic stenosis and a small aortic annulus undergoing transcatheter aortic valve replacement, hemodynamic parameters were best with a self-expanding valve, according to data from the SMART trial.

ATLANTA — In patients who underwent early angiography for acute MI and had ejection fraction of 50% or more, long-term beta-blocker use did not reduce risk for death or new MI compared with no use, researchers reported.

ATLANTA — Transcatheter implant of an inter-atrial shunt had drastically different results depending on ejection fraction in patients with HF, a speaker reported at the American College of Cardiology Scientific Session.

The 2024 American College of Cardiology Scientific Session will be held live in Atlanta from April 6 to 8 and virtually, with 43 late-breaking trials and featured clinical research presentations.